Fingolimod: treatment monitoring
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Fingolimod: treatment monitoring. Electrocardiogram ECG, Ophthalmology assessment or optical coherence tomography. Fully referenced neurology checklist.
Pre-treatment assessments and monitoring
- Electrocardiogram ECG
- Ophthalmology assessment or optical coherence tomography
- Skin examination
- Full blood count
- Liver function tests: this is repeated at 3 and 6 months
- Pregnancy test
- Varicella zoster IgG screening: vaccinate the patient if this is negative
First dose ECG monitoring
Locked: subscribe to see this section.
Indications for extended ECG monitoring
Locked: subscribe to see this section.
Indications for continuous overnight ECG monitoring
Locked: subscribe to see this section.
References
- Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol 2016; 23(Suppl 1):18-27.
- Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 2011; 25:673-689.
- Kappos L, Radue EW, O'Connor P, et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis. NEJM 2010; 362:387-401.
- Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing−remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13:545–556.
- Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 2015; 29:565-575.
- And 3 more. Subscribe to see the full list
